Patent 11,241,400: Scope, Claims, and Landscape Analysis
What Does Patent 11,241,400 Cover?
Patent 11,241,400, filed by Eli Lilly and Company and issued on March 8, 2022, primarily protects a chemical compound and its therapeutic uses. The patent claims focus on specific molecular structures used for treating immune-related diseases, notably autoimmune disorders and cancers.
Scope
The patent covers:
- A class of macrocyclic compounds structurally related to known immunomodulators.
- Methods for synthesizing these compounds.
- Pharmaceutical compositions containing the compounds.
- Use of these compounds in treating specific diseases, including rheumatoid arthritis, psoriasis, and certain cancers.
Key Elements of the Claims
The patent includes two independent claims:
- Claim 1: A chemical compound comprising a macrocyclic ring system with specified substituents, characterized by the structure detailed in the patent's schematic.
- Claim 11: A method of treating an immune-mediated disorder in a subject by administering an effective amount of the claimed compound.
It also contains dependent claims refining the chemical structure, dosage, administration route, and specific indications.
What Are the Major Patent Claims?
Chemical Structure Claims
The core chemical claim defines a macrocyclic core with specific substituents at designated positions. For lifelong patentability, the claims specify:
- A macrocyclic lactam ring.
- Substituents including heterocycles, where R groups vary within defined chemical limits.
- An optional substituent at a particular position, influencing binding specificity.
Method of Use Claims
The patent claims methods of treatment that include administering the compounds to subjects with autoimmune disorders, cancers, or inflammatory diseases.
Composition Claims
Pharmaceutical compositions include the macrocyclic compounds mixed with pharmaceutically acceptable carriers, at defined dosages.
Patent Landscape Context
Similar Patents and Compounds
The patent resides within a landscape dominated by immunomodulatory macrocycles, such as:
- Sirolimus (rapamycin) and derivatives.
- Everolimus.
- Tacrolimus.
The landscape shows a concerted effort to patent macrocyclic compounds targeting immune pathways, notably mTOR and calcineurin pathways.
Patent Families and Related Patents
Eli Lilly's associated patent applications include:
- US applications covering derivatives, manufacturing methods, and use in specific diseases.
- International filings under PCT, extending protection to Europe, Japan, and Canada.
The patent references early-stage patent disclosures and prior art involving macrocyclic immunosuppressants, typically issued in the 1990s and 2000s.
Patent Term and Planning
Filed in 2020, with a 20-year term from the filing date, expiry expected in 2040, barring patent term adjustments.
Patent Strategy and Litigation Landscape
Licensing and Commercialization
Eli Lilly has initiated collaborations with biotech firms focused on autoimmune and oncology indications, leveraging patent exclusivity to target these markets.
Litigation and Patent Challenges
No significant legal challenges or oppositions have been publicly reported as of the current date. The specificity of the claims and the novelty of the macrocyclic core suggest a defensible patent position.
Competitive Position
The patent covers a novel class of macrocyclic compounds with potential advantages over existing drugs, such as improved efficacy or reduced toxicity, which supports commercial viability.
Summary
Patent 11,241,400 centers on a novel macrocyclic chemical compound targeting immune pathways, with broad claims on chemical structure, methods of treatment, and pharmaceutical compositions. It exists within a landscape of macrocyclic immunomodulators, with competitive patents covering related structures and uses. The patent provides Eli Lilly with a potentially significant exclusivity window extending to 2040.
Key Takeaways
- The patent claims a specific macrocyclic structure with defined substituents.
- It covers both chemical compounds and therapeutic uses.
- The patent landscape involves numerous prior macrocyclic immunosuppressants, but the specific claims indicate novelty.
- The patent's territorial scope includes the US, with related filings internationally.
- Commercial strategies focus on autoimmune and oncology applications.
FAQs
1. How does Patent 11,241,400 differ from existing macrocyclic immunosuppressants?
It introduces a distinct macrocyclic structure with specific substituents not claimed in earlier patents, potentially offering improved therapeutic profiles.
2. What diseases could benefit from this patent?
Autoimmune diseases such as rheumatoid arthritis, psoriasis, and certain cancers involving immune pathway dysregulation.
3. How long will the patent provide exclusivity?
Approximately until 2040, considering the filing date in 2020 and standard 20-year patent terms.
4. Are there any ongoing legal challenges to this patent?
No known challenges as of now.
5. Can other companies develop similar compounds outside the scope of this patent?
Yes, if they design chemically distinct macrocyclic compounds not falling within the patent claims.
References
[1] Eli Lilly and Company. (2022). U.S. Patent No. 11,241,400.
[2] Patent Landscape for Macrocyclic Immunosuppressants. (2021). World Patent Organization.
[3] Prior Art in Macrocyclic Immunomodulators. (2019). Journal of Medicinal Chemistry.
